Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213154 | 1.00 | SLC22A6 (0.38) | SLC22A6ENPEPTGFBR1CASRKDM4E | |
| SCHEMBL13930947 | 0.82 | SLC22A6 (0.38) | SLC22A6 | |
| SCHEMBL25436589 | 0.80 | SLC22A6 (0.37) | SLC22A6ENPEP | |
| SCHEMBL30528195 | 0.80 | SLC22A6 (0.37) | SLC22A6ENPEP | |
| SCHEMBL12256015 | 0.78 | CA14 (0.38) | SLC22A6RECQLSMN1; SMN2MMP13MEN1 | |
| SCHEMBL26714031 | 0.78 | CA14 (0.38) | SLC22A6RECQLSMN1; SMN2MMP13MEN1 | |
| SCHEMBL27346663 | 0.78 | SLC22A6 (0.35) | SLC22A6ENPEP | |
| SCHEMBL3261892 | 0.78 | SMN1; SMN2 (0.55) | ENPEPTGFBR1KDM4EMAPTTHRB | |
| SCHEMBL11156300 | 0.78 | SMN1; SMN2 (0.55) | ENPEPTGFBR1KDM4EMAPTTHRB | |
| SCHEMBL11156303 | 0.78 | SMN1; SMN2 (0.55) | ENPEPTGFBR1KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218168-B | Preparation method of sodium salt of N- (all-trans-retinoyl) -L-methyl cysteic acid | 上海现代药物制剂工程研究中心有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | INTOCELL, INC. (KR) | 2023-11-07 | — | — | US | disclosed |
| CN-112239418-B | Preparation method of retinol compound and sodium salt thereof | 上海现代药物制剂工程研究中心有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-110218168-B | Preparation method of sodium salt of N- (all-trans-retinoyl) -L-methyl cysteic acid | 上海现代药物制剂工程研究中心有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-110218168-B | Preparation method of sodium salt of N- (all-trans-retinoyl) -L-methyl cysteic acid | 上海现代药物制剂工程研究中心有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-110218168-B | Preparation method of sodium salt of N- (all-trans-retinoyl) -L-methyl cysteic acid | 上海现代药物制剂工程研究中心有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-2231189-A1 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES | Ardenia Investments Ltd. (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009078802-A1 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES | ARDENIA INVESTMENTS, LTD. (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009078754-A1 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES | ARDENIA INVESTMENTS, LTD. (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2004097427-A1 | METHODS FOR PEPTIDE ANALYSIS USING MASS SPECTROMETRY | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807628-B2 | Benzodiazepine derivatives and uses thereof | GABRB3, GABRB2, GABRB1 | SLC22A6 2705/4885ENPEP 2346/4885TGFBR1 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.